Key takeaways from Merck’s landmark covid IP licensing deal with the Medicines Patent Pool
The agreement is the first granting non-exclusive and royalty free rights to sub-licensees of a covid therapeutic or vaccine
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.